ACLARIS THERAPEUTICS INC's ticker is ACRS and the CUSIP is 00461U105. A total of 59 filers reported holding ACLARIS THERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is 0.02 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $12,368,000 | +151.7% | 1,911,573 | 0.0% | 0.74% | +102.2% |
| Q3 2020 | $4,913,000 | +58.6% | 1,911,573 | 0.0% | 0.36% | +86.7% |
| Q2 2020 | $3,097,000 | +55.8% | 1,911,573 | 0.0% | 0.20% | +6.0% |
| Q1 2020 | $1,988,000 | -45.0% | 1,911,573 | 0.0% | 0.18% | -29.2% |
| Q4 2019 | $3,613,000 | +75.0% | 1,911,573 | 0.0% | 0.26% | +39.0% |
| Q3 2019 | $2,064,000 | -50.7% | 1,911,573 | 0.0% | 0.19% | -51.4% |
| Q2 2019 | $4,186,000 | -63.4% | 1,911,573 | 0.0% | 0.38% | -65.1% |
| Q1 2019 | $11,450,000 | -18.9% | 1,911,573 | 0.0% | 1.10% | -37.3% |
| Q4 2018 | $14,127,000 | -36.8% | 1,911,573 | +24.2% | 1.76% | -11.7% |
| Q3 2018 | $22,353,000 | -63.6% | 1,539,480 | -50.0% | 1.99% | -49.2% |
| Q2 2018 | $61,486,000 | +128.0% | 3,078,960 | +100.0% | 3.92% | -15.4% |
| Q1 2018 | $26,972,000 | – | 1,539,480 | – | 4.64% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management V, LLC | 1,258,243 | $8,618,965 | 13.75% |
| Foresite Capital Management IV, LLC | 2,808,034 | $19,235,033 | 10.68% |
| Bain Capital Life Sciences Investors, LLC | 3,400,000 | $23,290,000 | 2.60% |
| GREAT POINT PARTNERS LLC | 1,691,768 | $11,588,611 | 2.11% |
| Samsara BioCapital, LLC | 696,171 | $4,768,771 | 1.46% |
| Altium Capital Management LP | 403,000 | $2,760,550 | 1.44% |
| BVF INC/IL | 7,064,736 | $48,393,442 | 1.30% |
| Aisling Capital Management LP | 434,455 | $2,976,017 | 1.23% |
| GREAT POINT PARTNERS LLC | 700,000 | $4,795,000 | 0.87% |
| VR Adviser, LLC | 1,040,754 | $7,129,165 | 0.75% |